As transaction volumes surge and regulatory expectations intensify, financial institutions are discovering that speed without intelligence introduces new forms of operational and compliance risk.

Non-inferiority trials are a valuable type of clinical trial to evaluate new treatments that might have differing benefits. Such trials are increasingly used, but have methodological challenges in ...